Prelude Therapeutics Incorporated
Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
Last updated:
Abstract:
The disclosure is directed to methods of treating disease using compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI: ##STR00001## ##STR00002##
Status:
Application
Type:
Utility
Filling date:
3 Apr 2020
Issue date:
14 Jul 2022